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Abstract
Background: The multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has emerged as a global
threat. Xinjiang is a multi-ethnic region and suffered second highest incidence of TB in China. However, epidemiological
information on MDR and XDR TB is scarcely investigated.
Methodology/Principal Findings: A prospective study was conducted to analyze the prevalence of MDR and XDR TB and
the differences of drug resistance TB between Chinese Han and other nationalities population at Chest Hospital of Xinjiang
Uygur Autonomous Region, China. We performed in vitro drug susceptibility testing of Mycobacterium tuberculosis to first-
and second-line anti-tuberculosis drugs for all 1893 culture confirmed positive TB cases that were diagnosed between June
2009 and June 2011. Totally 1117 (59.0%, 95% CI, 56.8%–61.2%) clinical isolates were resistant to $1 first-line drugs; the
prevalence of MDR TB was 13.2% (95% CI, 11.7%–14.7%), of which, 77 (30.8%; 95% CI, 25.0%–36.6%) and 31 (12.8%; 95% CI,
8.6%–17.0%) isolates were pre-XDR and XDR TB respectively. Among the MDR/XDR TB, Chinese Han patients were
significantly less likely to be younger with an odds ratio 0.42 for age 20–29 years and 0.52 for age 40–49 years;
Ptrend=0.004), and Chinese Han patients has a lower prevalence of XDR TB (9.6%) than all the other nationality (14.9%).
Conclusions/Significance: The burden of drug resistance TB cases is sizeable, which highlights an urgent need to reinforce
the control, detection and treatment strategies for drug resistance TB. However, the difference of MDR and XDR TB between
Chinese Han and other nationalities was not observed.
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Introduction
A third of the world’s population is estimated to be infected with
Mycobacterium tuberculosis (M.tuberculosis) according to the report of
World Health Organization [1]. The emergence and spread of
multidrug-resistant (MDR) and extensively drug-resistant (XDR)
tuberculosis (TB) is further hampering efforts to control and
manage the disease. Since the emergence of MDR strains in the
1990s, the prevalence of MDR TB has constantly increased. In
2008, about 440 000 MDR TB cases occurred in the world,
leading to an estimated 150 000 deaths. XDR TB is a nearly
untreatable form of the disease, and has been reported in 58
countries [2] with an estimated rate of 15% among the MDR
strains [3].
TB is a significant public health problem in mainland China
with an incidence around 100 per 100 000 populations [1].
Owning to the implementation of DOT’S plan, TB prevalence
used to be decreased by 30% [4]. However, the emergence of drug
resistance has severely threatened TB control in the country, and
has raised the concern of a return to an era in which drugs are no
longer effective [5]. According to National Baseline Survey on
Drug-resistant Tuberculosis in mainland China during 2007–
2008, 8.3% pulmonary TB patients were MDR based on the drug
susceptibility tests of M. tuberculosis isolates [6].
Xinjiang Uygur Autonomous Region has the second highest
incidence of TB among all the provinces and Autonomous
Regions in China. The estimated prevalence of active pulmonary
TB is 464 per 100 000, which might be caused by the spread of
the HIV infection, increasing of floating population, poor health
practices and bad living conditions in rural area, and with
approximate 6700 deaths each year [7]. Xinjiang is also a multi-
ethnic region, with minorities other than Han population
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The difference of TB incidence used to be observed between
ethnics [8], however, information on the prevalence of MDR and
XDR TB remain scant in the region, since the first and second-
line anti-TB drug susceptibility testing (DST) was not performed as
a routine test in most of the local hospitals and the available data
were not collected in a proper way to reflect the situation of the
MDR/XDR TB occurrence in the region. This has hindered the
informed efforts of disease control. The objectives of the study
were to estimate the prevalence of MDR and XDR TB, and to
investigate the differences in the drug-resistant profiles of TB
among various ethnic groups.
Results
Demographics of the study subjects
During June 2009 to June 2011, a total of 9759 clinically
diagnosed TB patients were enrolled at Chest Hospital of Xinjiang
Uygur Autonomous Region (CHXUAR), providing their sputa for
M. tuberculosis test. Of these 9759 TB patients, 2518 (25.8%) had a
positive acid-fast bacilli smear, and 7864 (80.6%) had a negative
culture. As a result, 1893 (19.4%) patients with culture positive
sputum were enrolled for anti-TB DST (figure 1). The age of the
1893 patients ranged from 2 to 95 years (mean (6SD), 43.0619.1,
media 40),57.2% of them were male and 48.5% of them were
Chinese Han people, and the others belonged to other nationality
groups. Majorities (85.5%) of them were inpatients and 37.4%
were newly diagnosed cases. All of the patients were negative for
HIV infection.
Resistance to the first-line drugs
Out of the 1893 M. tuberculosis isolates, 1117 (59.0%; 95% CI,
56.8%–61.2%) were resistant to at least 1 first-line drug, 36.2% (95%
CI, 34.0%–38.4%) were resistant to streptomycin, 36.1% (95% CI,
33.9%–38.2%) to isoniazid, 19.4% (95% CI, 17.7%–21.3%) to
rifampin, and 17.5% (95% CI, 15.8%–19.3%) to ethambutol (table 1).
Isolates from 249 patients were resistant to both isoniazid and
rifampin, resulting in a MDR TB rate of 13.2% (95% CI, 11.6%–
14.7%), which contain 89 newly diagnosed patients with MDR rate of
12.6% and 160 re-treatmentpatientswith MDR rate of 13.5%.Of the
249 MDR isolates, 176 (70.7%) demonstrated resistance to other first-
line drugs, including 111 (44.6%) were resistant to streptomycin, 23
(9.2%) resistant to ethambutol and 43 resistant (17.2%) to both.
Resistance to the second-line drugs
Overall, isolates from 32.5% (95% CI, 30.4%–34.7%) patients
were resistant to the second-line drugs. Fluoroquinolones had the
highest resistance rate (25.2%; 95% CI, 23.3%–27.2%), followed
by kanamycin (8.9%; 95% CI, 7.6%–10.2%), capreomycin (6.4%;
95% CI, 5.3%–7.5%), amikacin (6.0%; 95% CI, 5.0%–7.0%) and
prothionamide (4.5%; 95% CI, 3.6%–5.4%). Isolates from 69
(3.6%, 95% CI, 2.8%–4.5%) isolates were resistant to $3 second-
line drugs and 56 (2.96%; 95% CI, 2.2%–3.7%) fluoroquinolone
monoresistance isolates were detected.
Among the 249 MDR TB patients, 77 (30.9%; 95% CI, 25.1%–
36.7%) were identified as pre-XDR TB cases, 65 (26.0%), 6 (2.4%),
4 (1.6%) and 2 (0.8%) were resistant to fluoroquinolones, amikacin,
kanamycin and capreomycin, respectively. Of the MDR TB
patients, 31 (12.5%; 95% CI, 8.3%–16.6%) were XDR TB cases,
Figure 1. Determination of prevalence of tuberculosis (TB) and drug resistance among persons with suspected TB, Xinjiang Uygur
Autonomous Region, China, during June 2009–June 2011. MDR, multidrug-resistant; XDR, extensively drug-resistant.
doi:10.1371/journal.pone.0032103.g001
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11.2% and 13.1% for re-treatment patients; 17 patients were
resistant to $6 routinely tested drugs (12 patients were other
nationalityand only5 wereHanpeoples,and of5 XDR TBpatients
who were resistant to 8 drugs: isoniazid, rifampin, ethambutol,
streptomycin, fluoroquinolones, kanamycin, amikacin and capreo-
mycin, 4 were other nationality group and 1 was resistant to all
drugs test in the study), while the other patients were resistant to ,6
drugs and 1 patient to all drugs test in this study (table 1).
Characteristics of non-MDR, MDR/XDR, non-MXR MDR
and XDR TB patients
The characteristics of patients with MDR/XDR (n=249), non-
XDR MDR (n=218) and XDR TB (n=31) are summarized and
compared with those patients without MDR/XDR (n=1644,
table S1). No significant difference in the prevalence of MDR and
XDR was observed among sex, age, ethnic group, patient type and
treatment status. We found no significant differences between
patients with XDR TB and patients with MDR but not XDR
(non-XDR MDR) TB. There was a higher prevalence of XDR TB
in other nationality (14.9%, 20/134) than in Chinese Han patients
(9.6%, 11/115), although the difference did not attain significant
level (P=0.26, data not shown in the table S1).
To investigate the ethnic effects on heterogeneity of drug
resistance, we stratified the patients into Han and non-Chinese
Han sub-groups, and made further analysis on the ethnic specific
estimation and comparison (table 2 and 3). Two strata were defined
and the ethnic specific MDR/XDR prevalence was compared.
After the stratification analysis, patients with MDR/XDR TB were
significantly less likely to be younger (odds ratio [OR] 0.42 for age
20–29 years; 0.52 for age 40–49 years, table 2) with a Ptrend value
0.004 (data not shown in the table 3), while absent for sex, patient
typeandtreatment statusinChineseHanpopulation.Nosignificant
differences between patients with XDR TB and patients with MDR
but not XDR (non-XDR MDR) TB were observed (table 3).
Discussion
Although XDR TB is a new term, cases have been occurring for
over decade [9] and are now recognized worldwide [10]. It was
reported that XDR TB prevalence among MDR TB cases ranged
from 6.6% to 23.7% worldwide [11]. China has the second highest
prevalence of TB and MDR TB burden, but the information on
XDR TB is scant, which blocked treatment and control of TB to
some extent. The most recent surveillance data from Beijing and
Shanghai city and Shandong province in China showed that the
XDR TB cases accounted for 6.3%–18.7% of MDR TB cases
[12,13,14,15,16]. By analyzing first-and second-line drug resistance
profiles of 1893 clinical M. tuberculosis isolates from Xinjiang
Autonomous Region, we found that 13.2% TB patients met the
definition for MDR, of which, 30.8% TB patients were pre-XDR,
and 12.5% of MDR strains met the definition for XDR. However,
the XDR TB is relatively higher than the previous surveillance data
in Beijing and Shanghai but lower in Shandong province
[12,13,14,15,16]. Our study also provided the age difference of
the MDR/XDR TB distribution between Chinese Han and non-
Chinese Han population, in which the MDR prevalence decreased
with the age diminution compared with older population
(Ptrend=0.004) inconsistent with previous report in Japanese
population [17], while any association was not found in other
nationality population.
According to recent Meta-analysis study for drug-resistant TB
in China [18], the prevalence of MDR was estimated to be 5.3%,
which is significant lower than the surveillance data in Beijing,
Shanghai, Shandong and our study, also lower than the national
surveillance data of MDR (8.3%). Our study indicated that the
prevalence of MDR and XDR TB was 13.2% and 12.5% (among
MDR TB), respectively. Of the XDR TB, the other nationality
people (14.9%, 20/134) have a higher prevalence than Han
people (9.6%, 11/115). Variety of different ethnic groups in
genetic background, drug metabolism and life habits would be
responsible for the difference.
We also identified an important subset of patients with pre-
XDR TB, and majority of pre-XDR TB cases were resistant to
fluoroquinolines (84.9%). In a study of South Africa using a
convenience sample, 14% MDR isolates were found to be pre-
XDR [19]. These findings suggest that we must implement
strategies to identify and cure patients with pre-XDR TB before
Table 1. First and second line drug resistant frequency
among 1893 clinical Mycobacterium tuberculosis isolates, June
2009–June 2011, Xinjiang Uygur Autonomous Region, China.
Drugs No. isolates Rate, % (95% CI)
Overall first-line drug resistance 1117 59.0(56.8–61.2)
INH 683 36.1(33.9–38.2)
RFP 368 19.4(17.7–21.2)
SM 685 36.2(34.0–38.4)
EMB 332 17.5(15.8–19.3)
Overall MDR 249 13.2(11.6–14.7)
INH+RFP 73 3.9(3.0–4.7)
INH+RFP+SM 111 5.9(4.8–6.9)
INH+RFP+EMB 23 1.2(0.7–1.7)
INH+RFP+SM+EMB 42 2.2(1.6–2.9)
Overall second-line drug resistance 616 32.5(30.4–34.7)
FQ 477 25.2(23.2–27.2)
AMK 113 6.0(5.0–7.0)
CPM 121 6.4(5.3–7.5)
KAN 169 8.9(7.6–10.2)
PTA 85 4.5(3.6–5.4)
Overall pre-XDR 77 30.9(25.1–36.7)
FQ 65 26.1(20.6–31.6)
AMK 6 2.4(0.5–4.3)
CPM 2 0.8
*
KAN 4 1.6
*
Overall XDR 31 12.5(8.3–16.6)
FQ+AMK 7 2.8(0.7–4.9)
FQ+KNA 10 4.0(1.6–6.5)
FQ+AMK+CMP 1 0.4
*
FQ+AMK+KNA 1 0.4
*
FQ+CMP+KNA 1 0.4
*
FQ+AMK+CMP+KNA 4 1.6
*
FQ+AMK(2)/CPM(1)/KNA+PTA 3 1.2
*
FQ+AMK+CMP/KNA+PTA 3 1.2
*
FQ+AMK+CMP+KNA+PTA 1 0.4
*
CI, confidence interval; INH, isoniazid; RFP, rifampin, SM, streptomycin, EMB,
ethambutol; MDR, multidrug-resistant; FQ, fluoroquinolines (specifically
ciprofloxacin, levofloxacin and ciprofloxacin.); AMK, amikacin; CPM,
capreomycin; PTA: prothionamid, KAN: kanamycin.
*95%CI was not determined.
doi:10.1371/journal.pone.0032103.t001
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Characteristics No. (%) isolates OR
* (95%CI)
non-MDR MDR/XDR non-XDR MDR XDR MDR/XDR vs. non-MDR XDR vs. non-XDR MDR XDR vs. non-MDR
Sex
Male 503(88.1) 68(11.9) 63(92.6) 5(7.4) reference reference reference
Female 302(86.5) 47(13.5) 41(87.2) 6(12.8) 1.16(0.77–1.74) 1.97(0.54–7.23) 1.96(0.58–6.55)
Age group
,20 53(86.9) 8(13.1) 8(100) 0(0.0) 0.66(0.29–1.50) - -
20–29 183(92.0) 16(8.0) 15(93.8) 1(6.3) 0.40(0.21–0.73) 0.37(0.04–3.56) 0.24(0.03–2.07)
30–39 128(88.9) 16(11.1) 15(93.8) 1(6.3) 0.57(0.30–1.05) 0.45(0.05–4.20) 0.30(0.03–2.53)
40–49 147(90.2) 16(9.8) 14(87.5) 2(12.5) 0.50(0.27–0.92) 0.95(0.17–5.42) 0.56(0.11–2.87)
50–59 83(84.7) 15(15.3) 14(93.3) 1(6.7) 0.86(0.45–1.64) 0.48(0.05–4.45) 0.48(0.06–4.09)
$60 211(82.7) 44(17.3) 38(86.4) 6(13.6) reference reference reference
Patients type
Inpatients 668(87.2) 98(12.8) 90(91.8) 8(8.2) reference reference reference
Outpatients 137(89.0) 17(11.0) 14(82.4) 3(17.6) 0.68(0.38–1.23) 1.72(0.38–7.78) 1.03(0.24–4.37)
TB treatment
New 346(87.6) 49(12.4) 46(93.9) 3(6.1) reference reference reference
Retreatment 459(87.4) 66(12.6) 58(87.9) 8(12.1) 1.03(0.68–1.56) 1.70(0.41–7.13) 1.82(0.45–7.40)
CI, confidence interval; MDR, multidrug resistance; MDR/XDR, MDR TB and XDR TB; non-XDR MDR, MDR without XDR; OR, odds ratio; XDR, extensively drug resistance;
Boldface indicates significance.
*Adjusted for the characteristics for which adjusted ORs are shown.
doi:10.1371/journal.pone.0032103.t002
Table 3. Comparison of characteristics between MDR and XDR prevalence in non-Chinese Han population.
Characteristics No. (%) isolates OR
* (95%CI)
non-MDR MDR/XDR non-XDR MDR XDR
MDR/XDR vs.
non-MDR
XDR vs. non-XDR
MDR XDR vs. non-MDR
Sex
Male 441(86.1) 71(13.9) 60(84.5) 11(15.5) reference reference reference
Female 398(86.3) 63(13.7) 54(85.7) 9(14.3) 1.02(0.71–1.48) 0.89(0.32–2.48) 0.89(0.36–2.18)
Age group
,20 70(94.6) 4(5.4) 4(100) 0(0) 0.46(0.15–1.39) - -
20–29 222(84.1) 42(15.9) 36(85.7) 6(14.3) 1.51(0.87–2.60) 0.71(0.18–2.85) 1.01(0.30–3.42)
30–39 158(84.5) 29(15.5) 25(86.2) 4(13.8) 1.44(0.80–2.61) 0.67(0.15–3.08) 0.96(0.25–3.72)
40–49 92(82.9) 19(17.1) 15(78.9) 4(21.1) 1.65(0.85–3.19) 1.00(0.21–4.82) 1.62(0.42–6.25)
50–59 106(86.2) 17(13.8) 16(94.1) 1(5.9) 1.43(0.73–2.82) 0.20(0.02–2.10) 0.32(0.04–2.79)
$60 191(89.3) 23(10.7) 18(78.3) 5(21.7) reference reference reference
Patients type
Inpatients 728(85.4) 124(14.6) 107(86.3) 17(13.7) reference reference reference
Outpatients 111(91.7) 10(8.3) 7(70.0) 3(30.0) 0.54(0.27–1.08) 3.85(0.77–19.23) 1.58(0.43–5.77)
TB treatment
New 273(87.2) 40(12.8) 33(82.5) 7(17.5) reference reference reference
Retreatment 566(85.8) 94(14.2) 81(86.2) 13(13.8) 1.20(0.80–1.79) 0.83(0.29–2.38) 0.87(0.34–2.22)
CI, confidence interval; MDR, multidrug resistance; MDR/XDR, MDR TB and XDR TB; non-XDR MDR, MDR without XDR; OR, odds ratio; XDR, extensively drug resistance;
Boldface indicates significance.
*Adjusted for the characteristics for which adjusted ORs are shown.
doi:10.1371/journal.pone.0032103.t003
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unless evolution of MDR TB into XDR TB is slowed, the number
of XDR TB cases could increase exponentially [20].
Traditionally, TB control efforts were focused mainly on
improvement of cure rates for drug-susceptible disease to reduce
the number of drug-resistant cases arising from acquired resistance
[21].However,manyhealthsystemsand nationalTBprogramhave
performed poorly during the past two decades due to recruit and
train sufficient health workers [22] and to regulate drug suppliers
and pharmacies [23]. Another important issue has been the failure
to provide free treatmentfordrug-susceptibledisease,which created
ideal environment for acquisition of drug resistance [24]. Addition-
ally, treatment costs for MDR TB was high, especially for these who
lived in the village and low income patients, leading to similarly
poor-quality treatment of MDR TB with second-line drugs, which
hasgiven riseto second-line drug resistance and emergenceof XDR
strains. China is a developing country, although the high speed
increasing of economy in recent years. A relatively large regional
difference in economic development is uneven, resulting in a high
incidence of TB in rural areas than in the cities. Although the
Chinese government in recent years implemented a new health care
system, there is no enough money for them to go to a good hospital
formedicaltreatmentfromthediseaseonset.MostTBpatientsfrom
the rural areas were always received an intermittent treatment due
tolackofmoney,increasingthe possibilityoftheprevalenceofdrug-
resistant strains. Evermore, the current standard care of TB patients
in China (National Tuberculosis Program) does not include the first-
and second-line anti-TB DST because of its prohibitive cost. All of
these factors could confound the high prevalence of MDR and
XDR TB in China.
The limitations of the current study should address. This study
was carried out in only one specialized TB hospital in Xinjiang,
the results might not reflect overall situation in the region; this
hospital is the largest specialized hospital for TB in the region and
provides medical care for TB patients of all ethnics throughout the
region. There is no selection bias on the demographic character-
istics of the patients. However, this hospital might have higher
inclusion rate of serious TB cases than other hospitals in the
region, whether this selection bias might lead to overestimation of
drug resistant tuberculosis is unclear. Moreover, the outcome of
XDR TB patients failed to be investigated due to the difficulty in
following up of the patients.
In conclusion, the transmission of drug-resistant TB among
Chinese population is extensive and widespread, the prevalence of
MDR TB remains high, and the presence of pre-XDR and XDR
TB will impose a new challenge in the control of TB. However,
the ethnic difference would not affect the prevalence of MDR and
XDR TB in Xinjiang Uygur Autonomous Region. Continuous
surveillance of clinical isolates of M. tuberculosis is needed to identify
MDR TB or XDR TB, especially in patients with a history of TB
and those who have received prior anti-TB treatment.
Materials and Methods
Ethical Approval
Individual participants gave written informed consent before
enrollment in the study. We obtained parental consent and patient
assent for participants ,1 8y e a r so fa g e ,a n dap a r e n ts e r v e da sa
proxy for the interview of participants ,13 years of age. The study
was approved by the institutional review board at CHXUAR, China.
Setting and study subjects
The study was conducted from June 2009 to June 2011 at the
CHXUAR, which is the largest specialized hospital for TB in the
region and provides medical care for .9% of the total TB patients
throughout the region. CHXUAR is the provincial level reference
laboratory and laboratory diagnosis center for TB, also the
Revised National Tuberculosis Control Program accredited
laboratory for DST. The laboratory participates and passes the
annual external quality assessment (EQA) of regional level and
national level, which made the laboratory accredited for the DST.
All the patients with clinically diagnosed TB at both outpatient
and inpatient settings were invited to participate the study. Three
sputum samples were collected prior to treatment initiation for
newly diagnosed patients and during the treatment for previously
diagnose patients, which were subject to acid-fast bacilli smear
microscopy detection and culture for M. tuberculosis Those who
were confirmed to be culture positive were enrolled for further
DST.
Drug susceptibility testing
Sputum for this study was tested by optical microscopic analysis
of Ziehl-Nielsen–stained smears and Middlebrook 7H11 agar and
Mycobacterial Growth Indicator Tube (MGIT) 960 broth system
(Becton Dickinson, Franklin Lakes, NJ, USA) culture. DST of
positive cultures were performed by using MGIT 960 System at
the following concentrations: isoniazid 0.2 mg/mL, rifampin
1.0 mg/mL, ethambutol 7.5 mg/mL, streptomycin 2.0 mg/mL,
ofloxacin 2 mg/mL, levofloxacin 2 mg/mL, kanamycin 5.0 mg/
mL, capreomycin 10 mg/mL, amikacin10 mg/mL, prothionamide
5 mg/mL, and ciprofloxacin 1.0 mg/mL. Because levofloxacin,
ciprofloxacin and ciprofloxacin are fluoroquinolones with full
cross-resistance, they were considered as the same family of anti-
TB drugs and represented by fluoroquinolones in our analysis.
MDR TB is defined as resistance to the two first-line drugs,
rifampicin and isoniazid. XDR TB is resistant to rifampicin and
isoniazid, plus any fluoroquinolone and one of the injectable
second-line drugs (amikacin, capreomycin, or kanamycin) [3]. Pre-
XDR TB was defined as TB with resistance to isoniazid and
rifampin and either a fluoroquinolone or a second-line injectable
agent but not both [25]. All the tests were performed at the
CHXUAR TB reference laboratory.
Data collection and statistical analysis
Medical records of the enrolled patients were reviewed for
demographic and clinical data. Information was obtained on sex,
age, ethnic, previous history of TB, present address and medical
records (such as presence of HIV infection, chest radiograph
findings). The continuous variables were expressed as group means
6 standard deviation (SD). The proportion was described by using
a frequency with its 95% confidence interval (CI) by single-sample
t test. Chi square test or Fisher’s exact test was used for inter group
comparison as appropriate. In bivariate analysis were included in a
multivariate logistic regression model. Two-tailed P value of less
than 0.05 was considered to be statistically significant.
Supporting Information
Table S1 Demographic and clinical characteristics
between XDR TB and non-XDR MDR TB from Xinjiang,
June 2009–June 2011.
(DOC)
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